Treatment
Cell clinical trials
We’re tracking 5,550 recruiting studies that include Cell, each written for real people, not researchers, below.
Recruiting studies
- NCT05759793RecruitingPhase 1
CAR T trial for relapsed myeloma targeting GPRC5D
This Phase 1 trial tests a CAR T-cell treatment made to find a specific marker called GPRC5D on myeloma (or plasma cell leukemia) cells. It may help people whose disease has returned or hasn’t responded to several prior treatments.
ShanghaiAges 18–75 - NCT05421364Recruiting
Boosting your own immune cells to improve the uterine lining
This study gives a small amount of your own immune cells into the uterus to change the immune environment in the uterine lining. It aims to improve how the uterine lining supports implantation, especially for people trying to conceive with embryo transfer of normal (euploid) embryos.
Sofia, SofiaAges 20–50 - NCT07075328RecruitingPhase 1/Phase 2
Study of OJP-001 for adult T-cell leukemia/lymphoma
This trial tests a new drug called OJP-001 for people with adult T-cell leukemia/lymphoma (ATL) that has come back or not responded to other treatments. The goal is to see if this drug can help control the disease.
Fukuoka, FukuokaAges 20–85 - NCT07065344Recruiting
A study of patients with DLBCL in the Middle East and Africa
This study looks at patients with diffuse large B-cell lymphoma (DLBCL) in the Middle East and Africa. It aims to understand how the disease is treated, what treatments are available, and how patients access newer therapies. You simply continue your regular care and the study team collects information.
Al MansurahAges Any age - NCT07075471Recruiting
MOVE: TGCT patient experience with vimseltinib
This study is collecting real-world data from people with TGCT who have been prescribed vimseltinib. It is not testing the drug itself — it simply tracks your experience to help doctors understand how the treatment works outside of a clinical trial.
Wilmington, North CarolinaAges 18 years+ - NCT07070518RecruitingPhase 1/Phase 2
Study of GV20-0251 for advanced solid tumors
This trial tests a new study drug, GV20-0251, for people with advanced solid tumors that no longer respond to standard therapies. It aims to see if the drug can shrink tumors or slow their growth.
Beijing, Beijing MunicipalityAges 18 years+ - NCT04977791Recruiting
Study how drug resistance develops in lung cancer immunotherapy
This study looks at lung tumor tissue and blood to understand why immune checkpoint drugs can stop working in non-small cell lung cancer. It may help researchers find better ways to predict and overcome drug resistance.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT07070648Recruiting
Predicting DLBCL treatment response with ctDNA and PET scans
This trial uses a blood test (ctDNA) and PET scans to predict how well standard first-line treatment works for diffuse large B-cell lymphoma (DLBCL). It aims to find out if these tests can guide better care.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT07070011Recruiting
Studying tiny particles in blood to predict treatment response in lung cancer
This trial looks at small particles called extracellular vesicles in your blood to see if they can help predict how well immunotherapy combined with chemotherapy will work for extensive-stage small cell lung cancer. The goal is to find markers that could guide future treatment decisions.
ShanghaiAges 45–80 - NCT07075523Recruiting
Brain scans and markers after CAR T-cell therapy
This study uses brain scans and blood markers to understand how CAR T-cell therapy affects the brain. It may help researchers predict or manage potential side effects.
La Jolla, CaliforniaAges 18 years+ - NCT07075510RecruitingPhase 1/Phase 2
Comparing Daratumumab injection in thigh vs. abdomen for plasma cell disorders
This trial is for people with multiple myeloma or AL amyloidosis who are about to start treatment with a drug called daratumumab. It compares two places to inject the medicine (thigh vs. abdomen) to see which works better and is more comfortable.
Baltimore, MarylandAges 18 years+ - NCT07072494RecruitingPhase 1/Phase 2
CD19 CAR-T cells as consolidation for B-cell ALL
This trial tests a single infusion of CD19 CAR-T cells as a consolidation treatment to keep leukemia in remission for patients who are not eligible for or decline a stem cell transplant. The goal is to see if this therapy can prevent relapse.
Guangzhou, GuangdongAges 14–80 - NCT07073703Recruiting
A personalized program for frailty in bladder or kidney cancer patients
This trial tests a personalized 6-month program to reduce frailty in older patients who are about to have surgery for bladder or kidney cancer. The program includes exercise and support, and aims to help patients stay stronger during and after treatment.
Saint-EtienneAges 65 years+ - NCT07065279Recruiting
JY231 injection for relapsed B-cell blood cancers
This trial tests a new treatment, JY231, for people with B-cell blood cancers that have come back or not responded to other treatments. It aims to see if this therapy can help when other options have stopped working.
Kunming, YunnanAges 2–75 - NCT07067255RecruitingPhase 1/Phase 2
Sequential CAR-T cells for advanced ovarian cancer with CD146 and GPC3
This trial tests a new type of immunotherapy called CAR-T cells that are designed to attack ovarian cancer cells that have two specific markers (CD146 and GPC3). It is for people with advanced ovarian cancer who have already tried standard treatments like platinum-based chemotherapy and need new options.
Beijing, Beijing MunicipalityAges 21–90 - NCT07066982RecruitingPhase 1/Phase 2
CAR T cells targeting CD146 and HER2 for advanced sarcomas
This trial tests a new type of immunotherapy where your own immune cells are modified to find and attack sarcoma cells that carry markers called CD146 or HER2. It is for people with advanced sarcoma who have already tried standard treatments.
Beijing, Beijing MunicipalityAges 21–90 - NCT07063745RecruitingPhase 2/Phase 3
Comparing a new drug combo for advanced lung cancer with a specific gene change
This trial tests a new drug called Navlimetostat combined with pembrolizumab and chemotherapy versus a placebo with the same standard treatments. It is for people with metastatic non-small cell lung cancer that has a specific missing gene (MTAP deletion) and who have not had prior treatment for their advanced disease.
Anchorage, AlaskaAges 18 years+ - NCT07059650RecruitingPhase 1/Phase 2
DZD8586 combo therapy for diffuse large B-cell lymphoma
This trial tests a new combination treatment (DZD8586) for people with diffuse large B-cell lymphoma (DLBCL). It looks at how well the drug works and how safe it is for both newly diagnosed patients and those whose cancer returned after initial treatment.
BeijingAges 18 years+ - NCT07059221RecruitingPhase 1/Phase 2
New drug combo for advanced head and neck cancer
This trial tests a new combination of drugs (SHR-A2102 and Adebrelimab) with or without other anti-cancer therapies for head and neck cancer that has come back or spread. It aims to see if these treatments can shrink tumors or slow the disease.
Chongqing, Chongqing MunicipalityAges 18–75 - NCT07056556RecruitingPhase 1
Study of BL-M09D1 for advanced lung and other solid tumors
This trial tests a new drug, BL-M09D1, in people with advanced non-small cell lung cancer or other solid tumors that have not responded to standard treatments. The goal is to see if the drug can help shrink or control the cancer.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT07060261Recruiting
Pre-op MRI for HPV+ tonsil cancer surgery
This trial is looking at whether an MRI before surgery can help improve outcomes for people with HPV-positive tonsil cancer who are undergoing robotic surgery (TORS). The results may help doctors better plan surgery to remove all cancer.
Cleveland, OhioAges 18 years+ - NCT07061444Recruiting
Breathing muscle training for stem cell transplant patients
This trial tests different breathing exercises to help people recover after a stem cell transplant. It looks at whether these exercises can improve strength and recovery.
Istanbul, ZeytinburnuAges 18–65 - NCT07055841RecruitingPhase 2
Study of PD-L1 antibody plus chemo before surgery for head and neck cancer
This trial tests whether adding a PD-L1 antibody (Adabelimab) to standard chemotherapy before surgery can help treat advanced head and neck squamous cell carcinoma. It is for people who have not had treatment for this cancer before and are well enough to undergo the therapy.
Jinan, ShandongAges 18–85 - NCT07057791RecruitingPhase 2
Chemo plus immunotherapy for extensive-stage small cell lung cancer
This trial tests a combination of chemotherapy (platinum/etoposide) plus an immunotherapy drug (ivonescimab) for people with extensive-stage small cell lung cancer who have not received treatment before. The goal is to see if adding the immunotherapy improves outcomes.
Miami, FloridaAges 18 years+
Common questions
- Are there clinical trials studying Cell?
- Yes. Clin2 currently lists 5,550 recruiting studies that include Cell, drawn from the U.S. registry and rewritten for real people so you can see what each is testing and who it's for.
- How do I know if I qualify for a Cell trial?
- Each study lists its own eligibility criteria — rules about condition, age, and prior treatments. On every Clin2 trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Is Cell an approved treatment?
- A drug being studied in a trial may be investigational (still being tested) or already approved and being studied for a new use. Each study page explains what phase it's in. Clin2 does not provide medical advice — talk with your doctor about whether Cell or a specific trial is right for you.
Related treatments
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. A drug appearing here is being studied in a trial and may be investigational. Talk with your doctor about whether a specific treatment or trial is right for you.